LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

Search

Guardant Health Inc

Open

BrancheGesundheitswesen

92.03 3.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

88.65

Max

97.67

Schlüsselkennzahlen

By Trading Economics

Einkommen

-36M

-128M

Verkäufe

16M

281M

EPS

-0.5

Gewinnspanne

-45.684

Angestellte

2,490

EBITDA

-37M

-119M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+40.51% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.5B

12B

Vorheriger Eröffnungskurs

88.85

Vorheriger Schlusskurs

92.03

Nachrichtenstimmung

By Acuity

50%

50%

166 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Mai 2026, 23:58 UTC

Ergebnisse

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. Mai 2026, 22:57 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. Mai 2026, 23:52 UTC

Ergebnisse

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. Mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. Mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. Mai 2026, 23:11 UTC

Ergebnisse

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. Mai 2026, 23:06 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. Mai 2026, 23:05 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. Mai 2026, 23:04 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. Mai 2026, 23:02 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. Mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. Mai 2026, 22:42 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. Mai 2026, 22:33 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. Mai 2026, 22:32 UTC

Ergebnisse

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie: 68% of FY Income From International >MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. Mai 2026, 22:29 UTC

Ergebnisse

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. Mai 2026, 22:26 UTC

Ergebnisse

Macquarie to End Share Buyback Extended in November>MQG.AU

7. Mai 2026, 22:25 UTC

Ergebnisse

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

40.51% Vorteil

12-Monats-Prognose

Durchschnitt 129.63 USD  40.51%

Hoch 175 USD

Tief 90 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

166 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat